BT-219

About Bridge Therapeutics

Bridge Therapeutics is a private, pre-revenue biotech founded in 2019, targeting the dual crises of chronic pain and opioid addiction. The company's strategy centers on two clinical-stage assets: BT-219, designed to improve the delivery of the established OUD treatment buprenorphine-naloxone, and BT-205, a combination therapy intended to allow chronic pain patients to transition off standard opioids without withdrawal or euphoria. Operating as a virtual or lean organization, Bridge is pursuing FDA approval for both programs, aiming to address significant unmet needs in a large and challenging market. The company's mission is to 'separate pain from addiction' by providing therapies that manage pain effectively while minimizing abuse potential.

Therapeutic Areas

Other Opioid Use Disorder (OUD) Drugs